Study questions certain breast cancer treatment

November 09, 2017 04:54 AM

Patients with estrogen receptor positive breast cancer typically are treated with either tamoxifen or aromatase inhibitors for five years after their cancer treatment finishes.

But a new study suggests that may not be long enough. Researchers at the University of Michigan looked at women with ER positive breast cancer. They found those who originally had large tumors had up to a 40 percent chance of a recurrence 20 years later.

Advertisement – Content Continues Below

Experts say it could indicate patients might need to stay on tamoxifen or other medication longer than five years.


WNYT Staff

Copyright 2017 - WNYT-TV, LLC A Hubbard Broadcasting Company

Relay Media Amp
Capital City Rescue Mission feeds more than 2,000 on Thanksgiving

Volunteers prep for Equinox Thanksgiving dinner

Macy's Thanksgiving parade revels on amid tight security

Thousands of people take part in Troy Turkey Trot

Trump credits troops, and himself, for military advances